abstract |
Rituximab and an IL-21 polypeptide or a fragment of an IL-21 polypeptide as shown in SEQ IDN: 2 from amino acid residue 30 to residue 162, for use in the treatment of cancer in a subject, in which rituximab and the IL-21 polypeptide are for administration once a week for up to eight consecutive weeks. |